Article

Multiplex Cripsr/Cas9 Genome Editing to Generate Potent Universal CART and PD1-Deficient Cells Against Leukemia

2015-12-03

Abstract excerpt

Abstract Engineered CAR T (CART) cell treatments of cancer patients have shown promising results. The majority of current CART clinical trials utilizes autologous T cells and might therefore be hampered by the poor quality and quantity of T cells as well as the time and expense of manufacturing autologous T cell products. These limitations would be circumvented by the use of allogeneic T cells. However, the endoge...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8365b0ff-e6ce-5e27-85ff-d6f21214d074
DOI: 10.1182/blood.v126.23.4280.4280

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Multiplex Cripsr/Cas9 Genome Editing to Generate Potent Universal CART and PD1-Deficient Cells Against LeukemiaDOI 10.1182/blood.v126.23.4280.4280Read

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 InhibitionSemantic proximity Read

Efficient Gene Editing of CART Cells with CRISPR-Cas12a for Enhanced Antitumor EfficacySemantic proximity Read

A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapiesSemantic proximity Read

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editingSemantic proximity Read

Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic EffectsSemantic proximity Read

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapySemantic proximity Read

CAR-T Therapy and CRISPR/Cas9 in Cancer TreatmentSemantic proximity Read

Elucidation of CRISPR-Cas9 Application in Novel Cellular Immunotherapy.Semantic proximity Read

Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemiaSemantic proximity Read

LLT1 overexpression renders allogeneic-NK resistance and facilitates the generation of enhanced universal CAR-T cellsSemantic proximity Read

CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapySemantic proximity Read

CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapySemantic proximity Read